The FDA has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis in patients aged 12 years and older who are AChR or anti-muscle-specific tyrosine kinase antibody ...

In this final part of a recent interview with Jonathan Strober, MD, UCSF Benioff Children's Hospital and phase 2/3 ...

Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

The FDA has approved Johnson & Johnson's anti-FcRn antibody, nipocalimab, for the treatment of generalized myasthenia gravis. The drug will be sold under the brand name IMAAVY. This approval ...

Myasthenia gravis is an autoimmune disorder in which antibodies disrupt the communication between nerves and muscles, ...

J&J’s JNJ stock has declined 6.4% in the past three months. J&J faces several challenges, including slowing sales in the ...

Nipocalimab has shown to be more effective than current treatment methods in preventing and managing HDFN. Johnson & Johnson’s nipocalimab, an investigational therapy currently being studied in ...

Earlier this year, nipocalimab data from Vivacity-MG3 supported the medication's long-term use in generalized myasthenia gravis when it is added to standard-of-care therapies. In particular ...

A new study found that cell-free DNA from routine prenatal testing can accurately identify preterm birth risk without added cost or procedures.

In another development, the FDA has approved Johnson & Johnson’s IMAAVY™ (nipocalimab-aahu) for treating generalized myasthenia gravis (gMG) in patients aged 12 and older. This approval is based on ...